Latest NexBio Inc. Stories
SAN DIEGO, Aug.
SAN DIEGO, Feb. 17, 2011 /PRNewswire/ -- NexBio, Inc. announced the presentation of "Treatment of Parainfluenza 3 Infection with DAS181 in a Patient after Allogeneic Stem Cell Transplantation" at the American Society for Blood and Bone Marrow Transplant meeting February 17-21 in Honolulu, Hawaii.
SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- NexBio, Inc. announced the presentation of new data at the 2010 annual American College of Allergy, Asthma, and Immunology in Phoenix, Arizona.
SAN DIEGO, June 18 /PRNewswire/ -- NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (FludaseÂ®) inhibits infection with multiple human parainfluenza virus (HPIV) strains.
SAN DIEGO, May 3 /PRNewswire/ -- NexBio, Inc.
SAN DIEGO, March 29 /PRNewswire/ -- NexBio, Inc. announced today the publication in the Journal of Infectious Diseases of a preclinical study suggesting that treatment with DAS181 (FludaseÂ®) may reduce the risk of secondary bacterial pneumonia following influenza virus infection.
SAN DIEGO, Calif., Feb. 8 /PRNewswire/ -- NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules".
SAN DIEGO, Jan. 19 /PRNewswire/ -- NexBio, Inc. announced today the appointment of Allen Chao, Ph.D., Founder, Chairman and former CEO of Watson Pharmaceuticals, to its Board of Directors as an independent director. Dr. Allen Chao is Chairman and Managing Partner, Newport Healthcare Advisors, LLC.
SAN DIEGO, Jan. 7 /PRNewswire/ -- NexBio, Inc. announced today the initiation of a double blind placebo controlled multi-center trial in the U.S. and Mexico of DAS181 (FludaseÂ®) for the treatment of laboratory confirmed influenza infection.
- Large; stout; burly.